Notably, the reduction in splenomegaly with Gal-1-mAb3 treatment was similar to that with fedratinib, a JAK2 inhibitor in clinical use (Fig. 6F), and no cytopenias were observed following galectin-1 inhibition in the control mice (Fig. 6C), indicating specific inhibition of the MPN clone rather than a non-specific cytoreductive impact. Here, JAK2 is linked to myeloproliferative disorder.